Brainomix AI Reveals Hidden Efficacy of ARG-007 in Severe Stroke Patients

Brainomix AI analysis of Argenica Therapeutics' Phase II trial uncovered statistically significant efficacy of ARG-007 in severe acute ischemic stroke patients with larger infarcts13

Brainomix 360 Stroke, an FDA-cleared AI platform, standardized baseline stroke severity assessment, revealing improvements in neurological function at 24 hours, better disability outcomes at 90 days, and smaller final infarct volumes compared to placebo12

The analysis, announced on December 18, 2025, addresses variability in manual stroke assessments, exposing a previously hidden treatment effect13

Findings will guide a targeted Phase 2b trial using precision medicine for patient selection13

Dr. Michalis Papadakis, Brainomix CEO, emphasized AI's role in precise patient phenotyping to accelerate therapies13

Dr. Liz Dallimore, Argenica CEO, highlighted ARG-007's benefits for patients with the largest strokes13

Sources:

1. https://www.prnewswire.com/news-releases/brainomix-ai-technology-reveals-efficacy-of-novel-neuroprotective-drug-candidate-in-severe-acute-ischemic-stroke-patients-302645077.html

2. https://www.brainomix.com/news/

3. https://www.bioindustry.org/resource/brainomix-ai-technology-reveals-efficacy-of-novel-neuroprotective-drug-candidate.html